Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4771 AL 4785

A comparative study of caregiver burden in late-onset depression and Alzheimer's disease

Kazhungil F, Velayudhan R, Kumar M, Thazhe Mangool R.

Psychogeriatrics. 2016 May;16(3):209-15. doi: 10.1111/psyg.12141. Epub 2015 Jul 16.

Impact of renin-angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: a meta-analysis

Ye R, Hu Y, Yao A, Yang Y, Shi Y, Jiang Y, Zhang J.

Int J Clin Pract. 2015 Jun;69(6):674-81. doi: 10.1111/ijcp.12626. Epub 2015 Feb 27.

CLINICAL PRACTICE. Advanced Dementia

Mitchell SL.

N Engl J Med. 2015 Jun 25;372(26):2533-40. doi: 10.1056/NEJMcp1412652.

Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias

Hennekens CH, Bensadon BA, Zivin R, Gaziano JM.

Expert Rev Neurother. 2015;15(11):1245-8. doi: 10.1586/14737175.2015.1088784. Epub 2015 Oct 8.

Why are spousal caregivers more prevalent than nonspousal caregivers as study partners in AD dementia clinical trials?

Cary MS, Rubright JD, Grill JD, Karlawish J.

Alzheimer Dis Assoc Disord. 2015 Jan-Mar;29(1):70-4. doi: 10.1097/WAD.0000000000000047.

Impact of a therapeutic educational program on quality of life in Alzheimer's disease: results of a pilot study

Villars H, Dupuy C, Perrin A, Vellas B, Nourhashemi F.

J Alzheimers Dis. 2015;43(1):167-76. doi: 10.3233/JAD-141179.

Physiotherapy intervention in Alzheimer's disease: systematic review and meta-analysis

Zhu XC, Yu Y, Wang HF, Jiang T, Cao L, Wang C, Wang J, Tan CC, Meng XF, Tan L, Yu JT.

J Alzheimers Dis. 2015;44(1):163-74. doi: 10.3233/JAD-141377.

Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study

Olde Rikkert MG, Verhey FR, Blesa R, von Arnim CA, Bongers A, Harrison J, Sijben J, Scarpini E, Vandewoude MF, Vellas B, Witkamp R, Kamphuis PJ, Scheltens P.

J Alzheimers Dis. 2015;44(2):471-80. doi: 10.3233/JAD-141305.

Trazodone and cognitive performance in Alzheimer disease

Camargos EF, Quintas JL, Louzada LL, Naves JO, Furioso AC, Nóbrega OT.

J Clin Psychopharmacol. 2015 Feb;35(1):88-9. doi: 10.1097/JCP.0000000000000237.

The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial

Nolan JM, Loskutova E, Howard A, Mulcahy R, Moran R, Stack J, Bolger M, Coen RF, Dennison J, Akuffo KO, Owens N, Power R, Thurnham D, Beatty S.

J Alzheimers Dis. 2015;44(4):1157-69. doi: 10.3233/JAD-142265.

Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor

Grossberg GT, Farlow MR, Meng X, Velting DM.

Curr Alzheimer Res. 2015;12(1):53-60. doi: 10.2174/1567205011666141218122835.

New horizons in the management of Alzheimer disease

Morley JE.

J Am Med Dir Assoc. 2015 Jan;16(1):1-5. doi: 10.1016/j.jamda.2014.10.022.

Cognitive-motor intervention in Alzheimer's disease: long-term results from the Maria Wolff trial

Muñiz R, Serra CM, Reisberg B, Rojo JM, Del Ser T, Peña Casanova J, Olazarán J.

J Alzheimers Dis. 2015;45(1):295-304. doi: 10.3233/JAD-142364.

Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease

Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM, Kook KA, Harrington CR.

J Alzheimers Dis. 2015;44(2):705-20. doi: 10.3233/JAD-142874.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias